Chemours(US:CC)2025-11-07 13:00Q3 2025 Financial Performance - Net sales were $1495 million, a decrease of $13 million compared to Q3 2024[8] - Adjusted EBITDA was $195 million, a decrease of $7 million compared to Q3 2024[8] - Opteon refrigerant net sales in TSS achieved 80% year-over-year growth[7] - Free cash flow was $105 million, with a free cash flow conversion rate of 54%[8] Segment Performance - TSS net sales were $560 million, with adjusted EBITDA of $194 million[18] - TT net sales were $612 million, with adjusted EBITDA of $25 million[18] - APM net sales were $311 million, with adjusted EBITDA of $14 million[18] Liquidity and Debt - Unrestricted cash and cash equivalents totaled $613 million as of September 30, 2025[21] - Net debt was $36 billion, with a net leverage ratio of 46x based on trailing twelve months Adjusted EBITDA[21] - Total liquidity was $16 billion, including $953 million of revolving credit capacity[21] Strategic Initiatives and Outlook - The company is on track to deliver approximately $125 million of gross cost savings by the end of 2025[32] - Full year 2025 Adjusted EBITDA is expected to be between $745 million and $770 million[39] - Full year 2025 capital expenditures are expected to be approximately $220 million[39]